Details for Patent: 8,686,034

Which drugs does patent 8,686,034 protect, and when does it expire?

Patent 8,686,034 protects HORIZANT and is included in one NDA.

This patent has thirty patent family members in twenty-three countries.

Summary for Patent: 8,686,034

Title:	Crystalline form of .gamma.-aminobutyric acid analog
Abstract:	A crystalline form of a .gamma.-aminobutyric acid analog, and methods of preparing same, are provided.
Inventor(s):	Estrada; Tono (Santa Clara, CA), Raillard; Stephen P. (Mountain View, CA), Frauenfelder; Christine (Glis, CH), Zacher; Uwe (Brig, CH)
Assignee:	XenoPort, Inc. (Santa Clara, CA)
Application Number:	13/164,620
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,686,034

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-002	Dec 13, 2011		RX	Yes	No						TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-002	Dec 13, 2011		RX	Yes	No						MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-001	Apr 6, 2011		RX	Yes	Yes						MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399-001	Apr 6, 2011		RX	Yes	Yes						TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

International Family Members for US Patent 8,686,034

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	516801
Australia	2004282192
Brazil	PI0415288
Canada	2541752
China	1867322
Cyprus	1113583
Denmark	1677767